What commercial partnership did ProBiotix Health announce for Lipok® reformulation in Spain and Portugal on 26 May 2026?

On 26 May 2026, ProBiotix Health said Lipok® reformulation in Spain and Portugal is at the commercial partnership stage under an exclusive supply agreement with Bioksan to replace red yeast rice.

ProBiotix Health — TickStock

Timeline

ProBiotix Health

3 stories · updated 23 Jul

ProBiotix strikes Belgian supply deal with Nutrisan

10:40, 23 Jul 2026

ProBiotix supplies LPLDL strain for iProbio’s CARDIObiom+ launch

09:31, 1 Jun 2026

ProBiotix Health signs exclusive Spain and Portugal supply deal with Bioksan

07:42, 26 May 2026

More in Healthcare Services

The image features a pair of hands wearing blue latex gloves forming a heart shape against a plain white background. This gesture symbolizes care and compassion, often associated with healthcare and safety.

Healthcare Services

One Health Group keeps hub build on track for spring 2027 opening

The NHS surgical provider says trading in early FY2027 remains strong as construction of its first surgical hub in Scunthorpe stays within budget and on schedule.

08:27, 11 Sept 2026

Healthcare Services

Personal Group extends Simplyhealth partnership, opens Hapi to new clients

08:07, 9 Sept 2026

Medtech & Diagnostics

Health & Bio Today: Inspiration Healthcare neonatal unit surges, Cambridge Nutritional Sciences, OptiBiotix, Novacyt, Genflow Biosciences

17:04, 8 Sept 2026

Medtech & Diagnostics

Novacyt secures IVDR certification for DPYD assay

09:22, 8 Sept 2026

Healthcare Services

Health & Bio Today: Spire agrees £1.03bn takeover, Futura Medical, MedPal AI, Incanthera, Ondine Biomedical, AstraZeneca, 4basebio

17:04, 7 Sept 2026

Healthcare Services

MedPal AI shares soar after August run rate update

Updated 11:16, 7 Sept 2026

Medtech & Diagnostics

Ondine's Steriwave piloted at Mexico's largest private hospital network

08:09, 7 Sept 2026

Healthcare Services

The Morning Brief: Spire Healthcare agrees £1.03bn takeover, Grainger, Ashmore, IQE

08:04, 7 Sept 2026

Healthcare Services

Spire Healthcare agrees £1.03bn takeover by Toscafund-led consortium

07:31, 7 Sept 2026

Mining & Metals

Small Caps Today: Jangada's investee stakes edge toward IPO paydays, Gem Diamonds, Futura Medical, Everyman Media

13:30, 3 Sept 2026

AI & Machine Learning

FDA clears Mounjaro for heart protection, MedPal flags market boost

16:17, 1 Sept 2026

ProBiotix Health develops and supplies patented probiotic strains and microbial ingredient technologies for cardiometabolic and metabolic-balance dietary supplements. The company commercializes its intellectual property through ingredient supply agreements and brand partnerships.

Sector: Healthcare Services
Market: AQSE

Insight

What supply agreement did ProBiotix Health announce for the LPLDL® strain?

ProBiotix Health based content on a company announcement describing a supply agreement for the LPLDL® strain, but the section does not provide further details such as terms, counterparties, or quantities.

Updated 23 Jul 2026

Insight

Which EU regulatory action does ProBiotix Health say is the principal market opportunity driver?

ProBiotix Health says regulatory action against Monacolin K in the EU is the principal market opportunity driver.

Updated 23 Jul 2026

Insight

Which partner does the editorial note identify as an early adopter of ProBiotix Health reformulation in Spain and Portugal?

Bioksan is identified as an early adopter in Spain and Portugal.

Updated 23 Jul 2026

Insight

What does ProBiotix Health supply for the Slovakia supplement CARDIObiom+® under its agreement with iProbio?

Under its cooperation with Slovak brand iProbio, ProBiotix Health supplies the active LPLDL® ingredient for CARDIObiom+® while iProbio handles manufacturing, packaging, branding, and initial direct e-commerce distribution.

Updated 23 Jul 2026

Insight

Which company partnered with ProBiotix Health to supply the LPLDL® probiotic strain for a new Nutrisan PRO product in Belgium?

ProBiotix Health partnered with Belgium’s Nutrisan to supply its patented LPLDL® strain for a new Nutrisan PRO standalone product in Belgium.

Updated 23 Jul 2026

Identifiers

Ticker: AQSE:PBX
Market: AQSE
ISIN: GB00BLNBFR86
LEI: 98450048683CF0388C30

Learn more on:

Official site GLEIF Companies House

Timeline

ProBiotix Health

ProBiotix strikes Belgian supply deal with Nutrisan

ProBiotix supplies LPLDL strain for iProbio’s CARDIObiom+ launch

ProBiotix Health signs exclusive Spain and Portugal supply deal with Bioksan

More in Healthcare Services

One Health Group keeps hub build on track for spring 2027 opening

Personal Group extends Simplyhealth partnership, opens Hapi to new clients

Health & Bio Today: Inspiration Healthcare neonatal unit surges, Cambridge Nutritional Sciences, OptiBiotix, Novacyt, Genflow Biosciences

Novacyt secures IVDR certification for DPYD assay

Health & Bio Today: Spire agrees £1.03bn takeover, Futura Medical, MedPal AI, Incanthera, Ondine Biomedical, AstraZeneca, 4basebio

MedPal AI shares soar after August run rate update

Ondine's Steriwave piloted at Mexico's largest private hospital network

The Morning Brief: Spire Healthcare agrees £1.03bn takeover, Grainger, Ashmore, IQE

Spire Healthcare agrees £1.03bn takeover by Toscafund-led consortium

Small Caps Today: Jangada's investee stakes edge toward IPO paydays, Gem Diamonds, Futura Medical, Everyman Media

FDA clears Mounjaro for heart protection, MedPal flags market boost

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer